2020 was supposed to be a blip. Instead it reshuffled the entire market. Volume recovered but the patient is completely different — and three years of stable post-COVID data says it's not going back.
Augmentation dropped from 287,085 to 193,073 in 2020 — a 33% single-year decline, the steepest in ASPS history. By 2022 it was back to 298,568, and by 2024 it reached 306,196. The volume story looks like a V-shaped recovery. But underneath the topline, every dimension of the market shifted permanently.
For 13 straight years the age distribution barely moved. Then COVID broke a long-standing equilibrium. The under-30 share halved from 29% to 16%. The 55+ share exploded 6x from 2.5% to 13.4%. The average patient aged 8–10 years in the space of four years.
The total breast surgery market grew 24% from 2018 to 2024 — from 598K to 740K procedures. Augmentation contributed exactly 0% of that growth. Lifts surged 40%, cosmetic reduction +76%, reconstruction +60%, and implant removals +41%.
| Procedure | 2018 | 2024 | Change |
|---|---|---|---|
| Augmentation | 313,735 | 306,196 | −2% |
| Breast lift | 109,638 | 153,616 | +40% |
| Reduction (cosmetic) | 43,635 | 76,734 | +76% |
| Reconstruction | 106,295 | 162,579 | +53% |
| Implant removal | 40,787 | 41,271 | +1% |
The 2020 data revealed which breast procedures patients considered urgent vs. deferrable. Augmentation (−33%) was the most postponable. Implant removal (+8%) and reconstruction (+1%) actually grew during the pandemic — patients pushed through lockdown barriers for procedures they considered essential.
The severity of the 2020 decline correlated with how "urgent" patients perceived the procedure. Purely elective augmentation was the most deferrable. Procedures addressing physical discomfort (lift, reduction) fell less. And procedures patients treated as essential — reconstruction and implant removal — didn't decline at all.
Three consecutive years of post-COVID data (2022–2024) confirm the reshuffling has stabilized. Each metric moved dramatically from 2018–2022, then barely moved from 2022–2024. The market found its new normal and is sitting in it. COVID didn't create new trends — it fast-forwarded existing ones by 5–7 years.